Header Logo

Connection

Stuart Levitz to Disease Models, Animal

This is a "connection" page, showing publications Stuart Levitz has written about Disease Models, Animal.
Connection Strength

0.942
  1. Oliveira LVN, Hargarten JC, Wang R, Carlson D, Park YD, Specht CA, Williamson PR, Levitz SM. Peripheral blood CD4+ and CD8+ T cell responses to Cryptococcus candidate vaccine antigens in human subjects with and without cryptococcosis. J Infect. 2025 Jul; 91(1):106521.
    View in: PubMed
    Score: 0.139
  2. Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLoS Pathog. 2024 Jul; 20(7):e1012220.
    View in: PubMed
    Score: 0.131
  3. Whelan AO, Flick-Smith HC, Walker NJ, Abraham A, Levitz SM, Ostroff GR, Oyston PCF. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model. PLoS One. 2024; 19(5):e0294998.
    View in: PubMed
    Score: 0.130
  4. Hester MM, Oliveira LVN, Wang R, Mou Z, Lourenco D, Ostroff GR, Specht CA, Levitz SM. Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis. Front Immunol. 2022; 13:1015586.
    View in: PubMed
    Score: 0.116
  5. Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P, Abraham A, Shen ZT, Lodge JK, Akalin A, Homan J, Ostroff GR, Levitz SM. Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017 11 28; 8(6).
    View in: PubMed
    Score: 0.083
  6. Guerra ES, Lee CK, Specht CA, Yadav B, Huang H, Akalin A, Huh JR, Mueller C, Levitz SM. Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma. PLoS Pathog. 2017 01; 13(1):e1006175.
    View in: PubMed
    Score: 0.078
  7. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. mBio. 2015 Dec 22; 6(6):e01905-15.
    View in: PubMed
    Score: 0.072
  8. Ramirez-Ortiz ZG, Lee CK, Wang JP, Boon L, Specht CA, Levitz SM. A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe. 2011 May 19; 9(5):415-24.
    View in: PubMed
    Score: 0.053
  9. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun. 2006 Jul; 74(7):3817-24.
    View in: PubMed
    Score: 0.038
  10. Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun. 2004 Mar; 72(3):1746-54.
    View in: PubMed
    Score: 0.032
  11. Specht CA, Lam WC, Hester MM, Lourenco D, Levitz SM, Lodge JK, Upadhya R. Chitosan-Deficient Cryptococcus as Whole-Cell Vaccines. Methods Mol Biol. 2024; 2775:393-410.
    View in: PubMed
    Score: 0.032
  12. Teitz-Tennenbaum S, Viglianti SP, Roussey JA, Levitz SM, Olszewski MA, Osterholzer JJ. Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection. J Immunol. 2018 10 01; 201(7):2004-2015.
    View in: PubMed
    Score: 0.022
  13. Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, Lee CG, Elias JA, Nielsen JN, Boulware DR, Bohjanen PR, Jenkins MK, Levitz SM, Nielsen K. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog. 2015 Mar; 11(3):e1004701.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.